| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10765628 | MAYNE PHARMA | Method of providing birth control |
Feb, 2039
(14 years from now) | |
| US10632066 | MAYNE PHARMA | Method of providing birth control |
Feb, 2039
(14 years from now) | |
| US10780047 | MAYNE PHARMA | Method of providing birth control |
Feb, 2039
(14 years from now) | |
| US10918649 | MAYNE PHARMA | System for providing birth control |
Jun, 2039
(15 years from now) | |
| US10925882 | MAYNE PHARMA | System for providing birth control |
Jun, 2039
(15 years from now) | |
| US11529308 | MAYNE PHARMA | System for providing birth control |
Jun, 2039
(15 years from now) | |
| US10940157 | MAYNE PHARMA | System for providing birth control |
Jun, 2039
(15 years from now) | |
Annovera is owned by Mayne Pharma.
Annovera contains Ethinyl Estradiol; Segesterone Acetate.
Annovera has a total of 7 drug patents out of which 0 drug patents have expired.
Annovera was authorised for market use on 10 August, 2018.
Annovera is available in ring;vaginal dosage forms.
Annovera can be used as method of preventing pregnancy by inserting a vaginal system containing 103 mg of segesterone acetate and 17.4 mg ethinyl estradiol into a vagina for up to thirteen 21/7-day (in/out) cycles, method of contraception by inserting a vaginal system for up to 13 21/7-day (in/out) cycles, wherein efficacy requires the system cannot be out of the vagina for more than 2 cumulative hours in any such cycle without using alternative contraception.
Drug patent challenges can be filed against Annovera from 10 August, 2022.
The generics of Annovera are possible to be released after 21 June, 2039.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 10, 2023 |
Drugs and Companies using ETHINYL ESTRADIOL; SEGESTERONE ACETATE ingredient
NCE-1 date: 10 August, 2022
Market Authorisation Date: 10 August, 2018
Treatment: Method of contraception by inserting a vaginal system for up to 13 21/7-day (in/out) cycles, wherein efficacy requires the system cannot be out of the vagina for more than 2 cumulative hours in any su...
Dosage: RING;VAGINAL
ANNOVERA family patents
